433 related articles for article (PubMed ID: 15145162)
41. Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer.
Maemura K; Shinchi H; Noma H; Mataki Y; Kurahara H; Maeda S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
Anticancer Res; 2008; 28(4C):2369-72. PubMed ID: 18751420
[TBL] [Abstract][Full Text] [Related]
42. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
43. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Vaishampayan UN; Ben-Josef E; Philip PA; Vaitkevicius VK; Du W; Levin KJ; Shields AF
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):675-9. PubMed ID: 12062611
[TBL] [Abstract][Full Text] [Related]
44. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
45. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
46. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
47. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
McGinn CJ; Zalupski MM; Shureiqi I; Robertson JM; Eckhauser FE; Smith DC; Brown D; Hejna G; Strawderman M; Normolle D; Lawrence TS
J Clin Oncol; 2001 Nov; 19(22):4202-8. PubMed ID: 11709563
[TBL] [Abstract][Full Text] [Related]
48. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514
[TBL] [Abstract][Full Text] [Related]
49. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
Jansen EP; Boot H; Saunders MP; Crosby TD; Dubbelman R; Bartelink H; Verheij M; Cats A
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1424-8. PubMed ID: 17689023
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
51. [Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer].
Mendlovic S; Symon Z; Kundel Y; Rabin T; Catane R; Pfeffer R
Harefuah; 2008 May; 147(5):384-7, 480. PubMed ID: 18770957
[TBL] [Abstract][Full Text] [Related]
52. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Velenik V; Anderluh F; Oblak I; Strojan P; Zakotnik B
Croat Med J; 2006 Oct; 47(5):693-700. PubMed ID: 17042060
[TBL] [Abstract][Full Text] [Related]
53. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
[TBL] [Abstract][Full Text] [Related]
54. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Pipas JM; Barth RJ; Zaki B; Tsapakos MJ; Suriawinata AA; Bettmann MA; Cates JM; Ripple GH; Sutton JE; Gordon SR; McDonnell CE; Perez RP; Redfield N; Meyer LP; Marshall JF; Cole BF; Colacchio TA
Ann Surg Oncol; 2005 Dec; 12(12):995-1004. PubMed ID: 16252135
[TBL] [Abstract][Full Text] [Related]
55. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
56. Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer.
Lu NN; Jin J; Wang SL; Wang WH; Song YW; Liu YP; Ren H; Fang H; Liu XF; Yu ZH; Li YX
PLoS One; 2015; 10(4):e0124601. PubMed ID: 25915948
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Wolff RA; Evans DB; Gravel DM; Lenzi R; Pisters PW; Lee JE; Janjan NA; Charnsangavej C; Abbruzzese JL
Clin Cancer Res; 2001 Aug; 7(8):2246-53. PubMed ID: 11489798
[TBL] [Abstract][Full Text] [Related]
58. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
[TBL] [Abstract][Full Text] [Related]
59. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Hudson E; Hurt C; Mort D; Brewster AE; Iqbal N; Joseph G; Crosby TD; Mukherjee S
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):27-35. PubMed ID: 19896352
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
